A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) - Sherman, SI; Jarzab, B; Cabanillas, ME (J Clin Oncol, 2011)
abstr 5503.